Australia seems poised to experience innovative therapy for excess weight: Retatrutide. This dual agonist – working on both GLP-1 and GIP receptors – demonstrates promising results in global studies, suggesting considerable reductions in BMI. While approval hasn't occurred with TGA, a number of individuals struggling weight-related health conce